Table 1. Clinicopathological characteristics of PC patient cohorts.
| Radical prostatectomy (n=267)a | Conservative treatment (n=111)a | |
|---|---|---|
| Median age, years (range) |
62 (46–72) |
75 (55–95) |
|
Gleason score, n (%) | ||
| 4–6 | 111 (41.6) | 37 (33.3) |
| 7 | 128 (47.9) | 20 (18.0) |
| 8–10 | 28 (10.5) | 53 (47.7) |
| Unknown |
— |
1 (0.5) |
|
T stage b, n (%) | ||
| T1 | — | 91 (82.0) |
| T2 | 159 (59.6) | 20 (18.0) |
| T3–4 |
108 (40.5) |
0 (0) |
|
PSA at diagnosis, n (%) | ||
| <10 ng ml−1 | 73 (27.3) | — |
| ⩾10 ng ml−1 | 193 (72.3) | — |
| Unknown |
1 (0.4) |
111 (100) |
|
Nodal status, n (%) | ||
| pN0 | 249 (93.3) | — |
| pN1 | 7 (2.6) | — |
| Unknown |
11 (4.1) |
111 (100) |
|
Metastasis status c, n (%) | ||
| M0 | 267 (100) | 111 (100) |
| M1 |
0 (0) |
0 (0) |
|
Surgical margin status, n (%) | ||
| Negative | 185 (69.3) | NA |
| Positive | 78 (29.2) | |
| Unknown |
4 (1.5) |
|
|
Early endocrine treatment, n (%) | ||
| No | 267 (0) | 68 (61.3) |
| Yes |
0 (0) |
43 (38.7) |
|
APN IHC, n (%) | ||
| Score 0 | 130 (48.7) | 69 (62.2) |
| Score 1+ | 79 (29.6) | 22 (19.8) |
| Score 2+ | 27 (10.1) | 4 (3.6) |
| Not determined | 31 (11.6) | 16 (14.4) |
| Median follow-up time, months (range) | 53 (1–131) | 61 (1–180) |
Abbreviations: APN=aminopeptidase N; IHC=immunohistochemistry; NA=not applicable; PC=prostate cancer; PSA=prostate-specific antigen.
Both cohorts were based on all consecutive patients visiting the clinic within a specified time period and diagnosed with clinically localised PC, where tissue blocks were available and informed consent obtained (see Materials and Methods for additional information).
Pathological for radical prostatectomy (RP) cohort and clinical for conservative treatment (CT) cohort.
M0 includes patients without suspicion of metastases at bone scan or X-ray examination as well as patients clinically regarded as having organ-confined disease without objective verification. M1 includes patients with metastases verified by bone scan or X-ray examination as well as patients with manifest clinical symptoms of metastases but without objective verification.